The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.

The result was keep. (non-admin closure) Goldsztajn (talk) 05:03, 2 February 2023 (UTC)[reply]

Alejandro Alagón Cano (edit | talk | history | protect | delete | links | watch | logs | views) – (View log | edits since nomination)
(Find sources: Google (books · news · scholar · free images · WP refs· FENS · JSTOR · TWL)

Fails WP:NPROF. References are completely unrelated to the topic. Could be a hoax, but I can't be arsed to investigate further. Headbomb {t · c · p · b} 13:32, 26 January 2023 (UTC)[reply]

  • Strong Keep I will say that initially when looking at this article I was teetering around a delete opinion, however upon further research I would disagree. Firstly, I would like to say I completely understand the article is in a horrible state, however it is certainly not irreparable. I have numerous reasons to support this point. Firstly, there is a generally healthy article about this exact same individual on the Spanish Wikipedia, as seen Here. This article is highly beneficial to us as it provides numerous sources, although most if not all are in Spanish. Per this, firstly I believe asserting it could be a hoax is just not true. I personally checked the FDA filing for Anascorp available Here which confirms Alejandro Alagón Cano was an active participant in development. As per "Failing Wikipedia:NPROF" I would argue this is not the case. --- As per the criteria "The person's research has had a significant impact in their scholarly discipline, broadly construed, as demonstrated by independent reliable sources." Obviously this is not accurate in the current state of the article, however this can be fixed with further research and hopefully translation from some Spanish Wikipedia friends! In fact, I would argue that further articles could be written extending from Alejandro Alagón Cano. Did you know that when Anascorp was approved by the FDA for use in the United States in 2011, it was the first ever Latin American drug to reach agency approval. I would argue that is rather notable in itself. Additionally, Anascorp is mentioned in numerous reliable sources regarding various topics, including cost of medication in the United States and the lengthy process of approval it underwent. According to a Stanford University source, (available here,) the researches who sought to investigate Anascorp's effectiveness tested over 200 children by 2010 in which had become (at that time) the largest ever anti-venom clinical trial in the world! Following my research I am going to investigate further into writing up an article for [[Anascorp]] and as a member of Wikipedia:Article Rescue Squadron, I will personally commit myself to making an attempt to repair the state of Alejandro Alagón Cano. Thank you for your time reading this and I hope you have a good day. ✯✬✩InterestGather (talk) 14:31, 26 January 2023 (UTC)[reply]
    None of those things can be used to demonstrate NPROF notability. The direct impact of the researcher must be discussed in independent, secondary coverage; having a drug approved by the FDA or the drug being tested in a trial are completely irrelevant if they aren't accompanied by significant commentary that describes the subject's involvement in those things. JoelleJay (talk) 19:03, 29 January 2023 (UTC)[reply]
The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.
No tags for this post.